Last update Feb. 19, 2019


Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a glycoprotein hormone, produced initially by the embryo and then by the placenta, obtained from the urine of pregnant women and composed of 2 subunits: alpha (smaller) and beta (larger); the latter confers specificity.
Administered via subcutaneous and intramuscular injection. Subcutaneous administration produces peak levels and later elimination.
Its effects are mainly those of the luteinizing hormone, responsible for triggering ovulation and the formation of the corpus luteum of the ovary in women and stimulating its hormonal production especially at the beginning of pregnancy (Sygma-Aldrich 2016).
Indicated to stimulate ovulation in assisted reproduction techniques. It is also used in threatened miscarriage and in cryptorchidism in children.
It is found naturally in small amounts in breastmilk (Lawrence 2016 p.139-147)

Since the last update we have not found published data on its excretion in breastmilk.

Its high molecular weight makes it very unlikely it will transfer into milk in significant quantities.

Due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.

May cause increased prolactin and galactorrhea (Mendes 2001).

No adverse effects have been reported in infants.

In infertility treatments, the possible theoretical anovulatory effect of frequent on demand breastfeeding must be taken into account.

See below the information of these related products:

  • Assisted Reproductive Techniques (ART) (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Choriogonadotropin Alfa (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Lutropin Alfa (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)


We do not have alternatives for G03GA01.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


G03GA01 belongs to this group or family:


Main tradenames from several countries containing G03GA01 in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 37.900 daltons
Tmax 6 - 20 hours
6 - 38 hours


  1. Sygma-Aldrich. Chorionic gonadotropin human. Drug Summary. 2016 Full text (in our servers)
  2. Mendes MC, Ferriani RA, Sala MM, Moura MD, Carrara HH, de Sá MF. Effect of transitory hyperprolactinemia on in vitro fertilization of human oocytes. J Reprod Med. 2001 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM